Stockscreener 앱 받기
121.74
0.37%
-0.45
시간 외 거래:
120.90
-0.84
-0.69%
전일 마감가:
$122.19
열려 있는:
$121.58
하루 거래량:
1.55M
Relative Volume:
0.90
시가총액:
$24.68B
수익:
$5.36B
순이익/손실:
$1.43B
주가수익비율:
17.21
EPS:
7.0718
순현금흐름:
$1.42B
1주 성능:
-2.14%
1개월 성능:
+1.31%
6개월 성능:
+31.55%
1년 성능:
+46.43%
1일 변동 폭
$119.97
$122.19
1주일 범위
$119.97
$127.72
52주 변동 폭
$81.09
$132.60
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
121.74 | 24.62B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
514.63 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.11 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
979.76 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.77 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.86 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance - TradingView
Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules - Stock Titan
Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services - marketscreener.com
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks - Yahoo Finance
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734 - Yahoo Finance
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte president Pablo Cagnoni sells $1.36m of INCY shares By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years - Benzinga
Insider Selling: Incyte (NASDAQ:INCY) Insider Sells $1,356,173.56 in Stock - MarketBeat
Incyte Corp's R&D Head Pablo J. Cagnoni Sells 10,801 Shares via 10b5-1 Trading Plan - Kalkine Media
Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards - Stock Titan
INCY Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Incyte (INCY) Quarter in Focus: The EPS Result Is Above Expectation for the Current Session; Stock Move: The Market Price Advances 4.05% on the DayRevenue Guidance Update - vinanet.vn
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $150 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on cancer trial data - Investing.com
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright - MarketBeat
Incyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on cancer trial data By Investing.com - Investing.com UK
Canaccord Genuity Initiates Incyte at Buy With $152 Price Target - marketscreener.com
DCF Advisers LLC Takes Position in Incyte Corporation $INCY - MarketBeat
BlackRock Inc. Takes $2.04 Billion Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation: Target Price Consensus and Analysts Recommendations | ICY | US45337C1027 - marketscreener.com
US FDA approves Regeneron's rare bone disorder drug - marketscreener.com
INCY Looks 19.9% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Incyte (INCY) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Reading - Vinanet
State of Wyoming's Incyte Corp(INCY) Holding History - GuruFocus
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
자본화:
|
볼륨(24시간):